Consult your healthcare professional to discuss the pros and cons of the treatment based on your current medical conditions, and to decide whether this combination is safe for you
Most patients see gradual reduction in abdominal fat over 36 months of treatment when combined with proper diet and exercise
The winning molecule, called liraglutide, entered clinical testing in 2000 as an injectable drug to treat diabetes, and would eventually be approved by the FDA, as Victoza in 2010
The cardiovascular effects of retatrutide are an area of active investigation
You should contact your GP, call NHS 111, or seek urgent medical advice if you are currently using unlicensed peptides and experience any of the following: Severe or persistent nausea, vomiting, or abdominal pain Signs of infection at an injection site (redness, swelling, warmth, discharge) Unexplained changes in heart rate or palpitations Symptoms of an allergic reaction (rash, swelling, difficulty breathing) Persistent right upper quadrant pain, fever, or jaundice (which may indicate gallbladder problems) Significant unintentional weight loss or fatigue Call 999 or go to your nearest emergency department if symptoms are severe or rapidly worsening